Hormonal
Weight loss significantly improves cardiovascular disease risk factors (triglycerides, HDL, glucose, insulin, CRP) only in individuals who are insulin resistant; insulin-sensitive individuals see little to no improvement in these metabolic markers despite similar weight loss.
If you are overweight and insulin resistant, weight loss will significantly improve your blood fats, blood sugar, and inflammation markers. If you are overweight but insulin sensitive, you will still lose weight, but your blood fats and sugar may not improve as dramatically. This suggests that targeting weight loss is most critical for those who are insulin resistant.
significant improvement in these metabolic abnormalities following weight loss is seen only in the subset of overweight/obese individuals that are also insulin resistant.
Why this rating
Controlled studies showing differential changes in metabolic markers post-weight loss.
Source
Obesity, Insulin Resistance, and Cardiovascular Disease
G M Reaven · Recent Progress in Hormone Research · 2004
DOI 10.1210/rp.59.1.207
More from this paper
- Obesity alone does not cause insulin resistance or elevated cardiovascular disease risk; rather, insulin resistance is the primary driver of metabolic abnormalities and CVD risk, regardless of body weight.Good
- Baseline insulin resistance does not predict the magnitude of weight loss achieved through calorie-restricted diets; both insulin-resistant and insulin-sensitive obese individuals lose similar amounts of weight.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →